The role of aberrant splicing in apoptosis and therapy resistance in T-cell leukemia Ghent University
Acute Lymphoblastic Leukemia (ALL) is an aggressive blood cancer with survival rates of only 50%. Especially high-risk and relapsed disease cases present with poor prognoses. Current frontline therapy includes DNA damaging chemotherapy and glucocorticoids. However, as only 15-20% of all relapsed ALL cases present with new genetic alterations, various non-genetic mechanisms have arisen recently at the forefront of therapy research. Among ...